From 11 Approvals to 80+ Trials: The ADC Innovation Surge
Antibody-drug conjugates had achieved more than 11 FDA approvals and over 80 investigational candidates in active clinical trials as of 2021–2022 — a trajectory reflecting a decade of sustained innovation in oncology biotherapeutics. ADCs combine the target specificity of monoclonal antibodies with the cytotoxic potency of small-molecule drugs through specialized chemical linkers, and the approved product list now spans hematologic malignancies, solid tumors, and increasingly novel indications.
The approved product benchmarks referenced across this dataset include brentuximab vedotin (Adcetris), ado-trastuzumab emtansine (Kadcyla), gemtuzumab ozogamicin (Mylotarg), inotuzumab ozogamicin (Besponsa), polatuzumab vedotin (Polivy), enfortumab vedotin (Padcev), trastuzumab deruxtecan (Enhertu), sacituzumab govitecan (Trodelvy), belantamab mafodotin (Blenrep), loncastuximab tesirine (Zynlonta), and mirvetuximab soravtansine (Elahere). Each represents a distinct manufacturing approach, and together they define the engineering benchmarks against which new entrants are measured.
Patent and literature records retrieved for this analysis span 2012 to 2025 and fall into three distinct innovation phases. The foundational period (2012–2015) established basic conjugate architecture. The site-specificity push (2016–2021) drove a pivot toward homogeneous drug-to-antibody ratio (DAR) products. The current process optimization phase (2022–2025) is accumulating IP around manufacturability, purification, and formulation — signaling that the competitive battleground has shifted from molecule design to manufacturing economics. According to FDA and WIPO, the biopharmaceutical sector’s patent activity in targeted oncology delivery has grown substantially over this period.
As of 2021–2022, more than 11 antibody-drug conjugates (ADCs) had received FDA approval and over 80 investigational ADC candidates were active in clinical trials, reflecting a decade-long innovation surge in oncology biotherapeutics.
The Conjugation Shift: From Stochastic Heterogeneity to Site-Specific Precision
The central manufacturing challenge in ADC development is controlling the drug-to-antibody ratio (DAR) — the number of cytotoxic drug molecules attached to each antibody. Stochastic conjugation to lysine ε-amino groups or partially reduced interchain cysteine residues produces heterogeneous DAR distributions of typically DAR 0–8, which directly complicates pharmacokinetics and batch-to-batch reproducibility. Site-specific conjugation methods, by contrast, yield defined DAR2 or DAR4 products with improved therapeutic index and pharmacokinetic predictability.
DAR measures how many cytotoxic payload molecules are conjugated to each antibody unit. Stochastic methods yield DAR 0–8 mixtures (confirmed by HIC-DAR analysis); site-specific methods target DAR2 or DAR4. A DAR of approximately 3.99 was measured in Multitude Therapeutics’ 2025 succinimidyl-thioether ADC by HIC-DAR analysis.
The most recent site-specific approaches documented in this dataset achieve homogeneous DAR profiles without requiring genetic engineering of the antibody. Ajinomoto Co.’s AJICAP Second Generation technology (2023) uses an Fc-affinity-reagent to mediate site-selective modification of Lys248 on native IgG1 antibodies, eliminating redox treatment and reducing aggregation. Separately, Synaffix BV’s chemoenzymatic tyrosine click chemistry approach (2021) uses antibody deglycosylation followed by tyrosinase-mediated ortho-quinone strain-promoted click chemistry to produce clean DAR2 and DAR4 ADCs with MMAE or PBD dimer payloads — again without recombinant DNA technology.
The Scripps Research Institute (2017) demonstrated a single-step conjugation approach using a naturally reactive buried lysine in a dual variable domain (DVD) format antibody at neutral pH without mutations. Together, these advances signal that the field is converging on site-specific methods that can be applied to unmodified native antibodies, reducing upstream manufacturing complexity while delivering the homogeneous DAR profiles that regulators and pharmacokineticists require. Research published through Nature and related journals has consistently validated that homogeneous DAR ADCs outperform heterogeneous mixtures in preclinical efficacy and safety models.
“In this dataset, the majority of 2020–2025 filings and publications favour homogeneous DAR2/DAR4 products — R&D teams entering the space should plan for enzymatic, bioorthogonal, or Fc-affinity-mediated conjugation from the outset rather than retrofitting stochastic processes.”
Site-specific ADC conjugation methods — including engineered cysteines, unnatural amino acids, glutamine via transglutaminase, glycan remodeling, and uniquely reactive lysines — yield homogeneous DAR2 or DAR4 antibody-drug conjugates with improved therapeutic index and pharmacokinetic predictability compared to stochastic lysine or cysteine conjugation, which produces heterogeneous DAR 0–8 distributions.
Map the full ADC conjugation patent landscape with PatSnap Eureka’s AI-powered search.
Explore ADC Patent Data in PatSnap Eureka →Linker-Payload Engineering: The Single Most Determinative Factor for ADC Therapeutic Window
Linker design is identified across multiple retrieved sources as the single most determinative factor for ADC therapeutic window. The linker must be stable in systemic circulation while efficiently releasing the cytotoxic payload in the tumor microenvironment — a dual requirement that drives the fundamental tradeoff between cleavable and non-cleavable linker chemistries.
Cleavable linkers — including pH-sensitive, protease-cleavable (Val-Cit-PABC), and disulfide formats — are designed to exploit the acidic or protease-rich tumor microenvironment for controlled payload release. Non-cleavable linkers rely on complete antibody degradation inside the lysosome. The Beijing Institute of Pharmacology and Toxicology (2021) reviewed the full landscape of chemical triggers, linker-antibody attachment strategies, and ADMET properties, identifying non-specific payload release as the dominant limitation of current linker designs.
Abzena Ltd. (2022) demonstrated that integrating cyclodextrin and crown ether macrocycles into bis-sulfone disulfide rebridging Val-Cit-PABC-MMAE reagents improves in vivo ADC performance, addressing the long-standing aggregation and clearance issues associated with hydrophobic payloads like MMAE. Brentuximab vedotin was used as the model antibody.
INATHERYS (EP, 2022) describes an anti-transferrin receptor (TfR) ADC using a Val-Cit dipeptide linker with a para-aminobenzyl self-immolative group and MMAE payload, with linker-antibody attachment via maleimide chemistry. This architecture — protease-cleavable linker, self-immolative spacer, maleimide attachment — represents the current mainstream design logic for cleavable ADC linkers.
The linker-payload design space remains open for innovation. Among retrieved sources, non-specific payload release and hydrophobicity-driven clearance are consistently cited as unsolved problems. Hydrophilic macrocycle-modified linkers (Abzena) and novel self-immolative chemistries represent IP white spaces for entrants with polymer or medicinal chemistry capabilities. The NIH National Cancer Institute has similarly highlighted linker stability as a critical unresolved parameter in ADC clinical development.
Linker design is identified in multiple ADC patent and literature sources as the single most determinative factor for ADC therapeutic window. Non-specific payload release in systemic circulation is the dominant limitation of current linker designs, as reviewed by the Beijing Institute of Pharmacology and Toxicology (2021).
Process Intensification and Manufacturing Cost Control
With more than 14 ADCs approved and dozens more in late-stage trials, differentiation is shifting from molecule design to manufacturing cost and robustness. The most recent patents in this dataset — filed 2022–2025 — concentrate heavily on conjugation reaction control, by-product removal, one-pot synthesis, and formulation stability.
Daiichi Sankyo’s 2024 Singapore patent describes a four-step manufacturing process: antibody reduction → drug-linker reaction → thiol-quenching of residual intermediates → ultrafiltration in strong acid/base salt buffer to remove aggregates and by-products. This ultrafiltration-based purification approach directly addresses the aggregation challenge that limits scalability of conventional ADC manufacturing.
Mabplex International’s 2023 EP patent takes a different approach: a one-pot preparation process that eliminates intermediate concentration, washing, and filtration steps, replacing them with a single separation/purification treatment. This is designed specifically for scale-up production economics. Shanghai Miracogen Inc. (2024, IL) addresses formulation stability with a citric acid buffer/trehalose/sodium chloride/polysorbate 80 formulation for an anti-EGFR ADC, targeting long-term stability of the Ab-(L-D)p conjugate structure.
These process patents signal that manufacturing IP is accumulating rapidly around scalable ADC production. For organizations with more than 14 approved ADCs and dozens in late-stage trials, process chemistry and purification are now the primary competitive differentiators. Standards bodies including EMA and ICH have issued guidance reinforcing the need for robust process controls and analytical characterization in ADC manufacturing submissions.
Identify white spaces in ADC process chemistry and formulation IP with PatSnap Eureka.
Analyse ADC Manufacturing Patents in PatSnap Eureka →Geographic and Assignee IP Landscape
Among the 20+ patent records with assignee and jurisdiction data in this dataset, Agensys, Inc. holds the highest filing volume with 6 active patent records across IL and EP jurisdictions from 2018 to 2021, all directed to auristatin-based ADCs binding the 191P4D12 tumor-associated antigen. INATHERYS follows with 4 active records (IL and EP, 2020–2025) focused on anti-TfR ADCs with Val-Cit-MMAE payloads. Novartis AG holds 3 records (IL, 2015–2017) covering anti-CDH6 and other oncology ADCs.
The Israel national phase (IL) is the dominant patent jurisdiction in this dataset with 13 records, largely reflecting PCT national phase entries. The European Patent Office (EP) accounts for 9 active records, with strong presence in novel target and process patents. Singapore holds 1 record (Daiichi Sankyo, 2024).
Among literature sources, the geographic distribution of innovation is notably broad. US institutions — Genentech, Sutro Biopharma, Eli Lilly, Scripps Research Institute, University of Southern California — and European institutions — Ajinomoto Japan, Synaffix Netherlands, Abzena UK, Leibniz Institute Germany, Sanofi France — are heavily represented. Chinese institutions including Huazhong University of Science and Technology, Zhejiang University, Tianjin Medical University, and Beijing Institute of Pharmacology feature prominently in literature, signaling growing Chinese research output. The Shanghai Miracogen formulation patent (2024, IL) and Multitude Therapeutics linker patent (2025, IL) indicate an emerging Chinese IP position in ADC manufacturing technology that will likely intensify through 2026.
In the ADC manufacturing patent dataset spanning 2012–2025, the Israel national phase (IL) is the dominant jurisdiction with 13 records, followed by the European Patent Office (EP) with 9 active records and Singapore (SG) with 1 record. Agensys, Inc. leads by filing volume with 6 active patent records, all directed to auristatin-based ADCs targeting the 191P4D12 tumor-associated antigen.
Emerging Directions: Non-Oncology, Bispecifics, and the Next Wave
The most recent records in this dataset (2022–2025) point to five forward-looking directions that will shape ADC manufacturing strategy through 2026 and beyond. Non-oncology applications represent the most significant paradigm shift: Visterra, Inc. (EP, 2024) discloses ADCs binding lipopolysaccharide (LPS) for treatment and prevention of bacterial infections — a notable departure from the oncology-dominant ADC paradigm. Antibody-siRNA conjugates (ARCs) for targeted RNA delivery are described in 2022 literature from Tianjin Medical University, signaling that ADC manufacturing know-how is being deliberately transferred to non-oncology therapeutic modalities.
Bispecific antibody-drug conjugate platforms represent another emerging direction. Seoul National University R&DB Foundation (EP, 2024) describes a cotinine-peptide-based modular platform enabling drug conjugation without multi-step synthesis, leveraging bispecific antibody architecture to enhance targeting and half-life simultaneously.
Site-specific conjugation without genetic engineering continues to advance. The AJICAP Second Generation (Ajinomoto, 2023) and the tyrosine click chemistry approach from Synaffix (2021) both achieve site-specificity on native, unmodified antibodies — reducing upstream manufacturing complexity while delivering homogeneous DAR profiles. These approaches are particularly significant for contract manufacturing organizations (CMOs) seeking to offer site-specific conjugation without requiring clients to re-engineer their antibody constructs. The EMA and regulatory agencies globally are increasingly scrutinizing DAR homogeneity as a critical quality attribute in ADC manufacturing submissions.
- Process intensification and one-pot manufacturing — Mabplex (EP, 2023) and Daiichi Sankyo (SG, 2024) signal a shift from multi-step batch processing to streamlined, single-vessel workflows with fewer purification cycles, critical for commercial cost control at scale.
- Novel linker architectures with hydrophilic modifiers — Abzena (2022) demonstrates that cyclodextrin or crown ether macrocycles in disulfide-rebridging reagents improve in vivo ADC pharmacokinetics, addressing aggregation and clearance issues of hydrophobic payloads like MMAE.
- Site-specific conjugation without genetic engineering — AJICAP Second Generation (Ajinomoto, 2023) and tyrosine click chemistry (Synaffix, 2021) achieve site-specificity on native IgG1 antibodies without protein engineering.
- Non-oncology ADC applications — Anti-LPS ADCs for bacterial infections (Visterra, EP, 2024) and antibody-siRNA conjugates (Tianjin Medical, 2022) signal deliberate transfer of ADC platform know-how to infectious disease and RNA delivery.
- Bispecific antibody-drug conjugate platforms — Seoul National University R&DB Foundation (EP, 2024) introduces a modular cotinine-peptide platform enabling conjugation without multi-step synthesis via bispecific antibody architecture.
“Chinese assignees and institutions are accelerating from literature to patents — the Shanghai Miracogen formulation patent (2024) and Multitude Therapeutics linker patent (2025) indicate an emerging Chinese IP position in ADC manufacturing technology that will likely intensify through 2026.”